Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds

Gut. 2021 Mar;70(3):623-624. doi: 10.1136/gutjnl-2020-321760. Epub 2020 Jun 17.

Authors

Cristina Bezzio¹, Gianpiero Manes², Francesco Bini³, Lucienne Pellegrini², Simone Saibeni²

Affiliations

¹ Gastroenterology Unit, ASST Rhodense, Garbagnate Milanese, Italy cribezzio03@yahoo.it.
² Gastroenterology Unit, ASST Rhodense, Garbagnate Milanese, Italy.
³ Pneumology Unit, ASST Rhodense, Garbagnate Milanese, Italy.

PMID: 32554621
DOI: 10.1136/gutjnl-2020-321760

No abstract available

Keywords: IBD.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Colitis, Ulcerative* / drug therapy
Gastrointestinal Agents / therapeutic use
Humans
Immunomodulation
Infliximab / therapeutic use
SARS-CoV-2

Substances

Gastrointestinal Agents
Infliximab